01 / Ancestry
Before a human name An evolutionary lineage, before recorded geography · Tens of millions of years agoDate basis: Modelled lineage divergence
Cannabis and hops belong to the same botanical family. Long before either became a crop, their ancestral lineages separated. Genes in living plants still carry traces of that relationship. Comparing them with a clock calibrated by fossils places the split millions of years before agriculture. The estimate describes a branching lineage, rather than the appearance of one first cannabis plant.
◌ Molecular dating estimate · 1 source
Read the evidence & its limits A 2023 hop-genome study estimated the Cannabis–Humulus divergence at about 22.6 million years ago using a fossil-calibrated Bayesian molecular clock. Its 95% highest posterior density interval extended from approximately 15.7 to 28.8 million years. Other methods in the same study produced estimates around 16–17 million years. The spread matters: fossil calibration, sampled genes and statistical method influence the date inferred from living genomes.
Where the evidence stops A molecular estimate is not a directly observed birth date. It does not identify the first cannabis individual, settle the plant’s precise birthplace, or establish where people first used it.
02 / Pollen
A trace in the sediment Northwestern China · northeastern Tibetan Plateau hypothesis · c. 19.6 million years agoDate basis: Age assigned to a pollen record
Tiny pollen grains offer another route into deep time. A record from northwestern China, dated to about 19.6 million years ago, resembles cannabis or hops. Researchers read the surrounding vegetation as a clue: open steppe favours a cannabis interpretation. A wider synthesis proposes an origin near the northeastern Tibetan Plateau, but the grains cannot settle the plant’s birthplace.
◌ Pollen synthesis and geographic hypothesis · 1 source
Read the evidence & its limits McPartland, Hegman and Long reviewed 155 Asian fossil-pollen studies in 2019. Their oldest Cannabis–Humulus pollen record consistent with cannabis was dated to about 19.6 million years ago in northwestern China. Because cannabis and hop pollen can be difficult to distinguish, they used accompanying steppe or forest pollen as ecological clues. Their proposed origin near Qinghai Lake also draws on the reconstructed history of steppe vegetation.
Where the evidence stops Pollen identification and ecological inference remain uncertain. This hypothesis does not establish a particular Himalayan valley as the plant’s origin, and it cannot reveal cultivation or the chemical composition of these ancient plants.
03 / Early encounters
Into human hands East Asia · Okinoshima, Chiba, Japan · About 12,000 years ago: model · 8280–7660 BCE: remainsDate basis: Genomic model and calibrated remains
At Okinoshima in Japan, excavated cannabis fruits put a tangible object into this story: remains dated to 8280–7660 BCE. A separate study of living genomes places an early domestication-related split around 12,000 years ago. These are different kinds of evidence for a long relationship in East Asia. Neither identifies the first grower or tells us what every seed was used for.
◌ Genomic inference and dated archaeobotany · 3 sources
Read the evidence & its limits A 2021 genomic study modelled a domestication-associated divergence around 12,000 years before present, with a broad 95% interval of roughly 6,458–15,728 years. Separately, directly dated Cannabis fruits from Okinoshima in Chiba have a calibrated range reported as 8280–7660 BCE in a later archaeobotanical review. The genomic result is an inference from modern samples; the Japanese finds are physical remains, with possible cultivation discussed by their investigators.
Where the evidence stops The genomic estimate is modelled elapsed time, not a calibrated radiocarbon date. The archaeological range uses calendar BCE. Neither establishes a first grower, a single route of spread or the use of every find.
Guangpeng Ren and colleagues · 2021 ↗ Large-scale whole-genome resequencing unravels the domestication history of Cannabis sativa Yuichiro Kudo, Makiko Kobayashi, Arata Momohara, Shuichi Noshiro, Toshio Nakamura, Susumu Okitsu, Seiichi Yanagisawa and Tozo Okamoto · 2009 ↗ Radiocarbon dating of fossil hemp fruits in the earliest Jomon period excavated from the Okinoshima site, Chiba, Japan Rita Dal Martello, Rui Min, Chris J. Stevens, Ling Qin and Dorian Q. Fuller · 2024; first published online 2023 ↗ Morphometric approaches to Cannabis evolution and differentiation from archaeological sites: interpreting the archaeobotanical evidence from bronze age Haimenkou, Yunnan
04 / Useful matter
Grain, thread, cloth Haimenkou, Yunnan · Gaocheng Taixi, Hebei · c. 1650–400 BCEDate basis: Archaeological context range
More than 800 cannabis grains survived in the ancient settlement of Haimenkou in Yunnan. Farther north, a roll of hemp cloth from Gaocheng Taixi records another use of the plant. The grains and cloth belong to separate places and periods. Together, they bring its material history into view, without revealing the purpose of every seed.
◌ Archaeobotany and material remains · 1 source
Read the evidence & its limits Haimenkou’s grains come from contexts dated about 1650–400 BCE, mostly one deposit from 1400–1100 BCE. The study also reviews hemp cloth from Shang-period Gaocheng Taixi, approximately 1600–1046 BCE. Seed measurements help investigate crop differentiation; they do not measure ancient cannabinoid chemistry.
Where the evidence stops These are separate sites and contexts. They do not demonstrate identical practices across China, reveal the use of every grain, or validate every proposed earlier hemp textile.
05 / Residue and ritual
What the brazier retained Jirzankal Cemetery · eastern Pamirs · c. 500 BCEDate basis: Dated archaeological context
In the eastern Pamirs, wooden braziers survived in graves at Jirzankal Cemetery. Chemical testing found traces consistent with cannabis burned around 500 BCE. The residues connect the plant to a funerary setting and support an interpretation of smoke inhalation. They preserve a physical trace of the ceremony, while leaving its words, meanings and individual experiences beyond our reach.
◌ Archaeological chemical-residue analysis · 1 source
Read the evidence & its limits A 2019 study analysed residues from braziers at Jirzankal, dated to about 500 BCE. Cannabinol, a degradation product associated with THC, supported the interpretation that cannabis was burned and its smoke inhaled during funerary rituals. The authors inferred relatively THC-rich material. This is among the earliest directly dated, chemically supported evidence for such ritual use; the study did not recover a measurable original THC percentage.
Where the evidence stops Chemical residues do not supply a complete ritual narrative or a modern potency comparison. This is not the first evidence of all cannabis use, nor evidence that the practice provided a medical benefit.
06 / Text and transmission
A plant in the written record China · the early bencao tradition · First–second centuries CEDate basis: Period assigned to a historical text
Cannabis appears in the Shen Nong Ben Cao Jing, a Chinese materia medica associated with the first and second centuries CE. Written entries preserve names and beliefs that a seed or a textile cannot. Later authors returned to those entries, sometimes disagreeing over which plant parts the names described. The text’s legendary association with Shennong is separate from its historical date.
◌ Historical medical-text scholarship · 1 source
Read the evidence & its limits Brand and Zhao’s 2017 review places the Shen Nong Ben Cao Jing in the first or second century CE. Their examination of Chinese medical literature distinguishes references to seed fruits from other plant parts and explores how historical terminology complicates interpretation. The work’s traditional association with Shennong does not date its composition to the third millennium BCE. Its historical indications require interpretation within the medical concepts of their periods.
Where the evidence stops A documented historical prescription is not modern clinical evidence. Legendary authorship should not become a dated discovery claim, and ancient plant-part names cannot always be mapped confidently onto current preparations.
07 / Language and knowledge
Reading the names carefully South Asia · Sanskrit medical and alchemical literature · Eleventh–thirteenth centuries CEDate basis: Periods assigned to historical texts
Vaṅgasena’s eleventh-century Cikitsāsārasaṃgraha contains a clear reference to ingestible medicinal or intoxicating cannabis. The later Ānandakanda discusses cultivation, preparations and dangers at greater length. These texts give the plant a more definite place in a medieval written record. Earlier names remain contested: tracing a manuscript’s language is different from establishing when people first encountered the plant in South Asia.
◌ Philology and historical textual research · 1 source
Read the evidence & its limits Patricia Sauthoff’s 2024 study revisits earlier philological research, including Dominik Wujastyk’s identification of an eleventh-century reference in Vaṅgasena’s Cikitsāsārasaṃgraha to ingestible medicinal or intoxicating cannabis. The twelfth–thirteenth-century Ānandakanda offers an extended discussion involving cultivation, preparations and dangers. The study also examines ambiguous names and challenges some retrospective identifications. These texts support a medieval written history; they do not establish when cannabis first reached or was used in South Asia.
Where the evidence stops Earlier bhaṅga references and identifications of soma are contested. Textual claims, mythology and prescriptions are not modern safety or efficacy findings, and no single manuscript establishes an Indian invention of cannabis use.
08 / Voices in the manuscript
Many voices, one herb Arabic literary and legal traditions · al-Badrī’s anthology · 14th–15th centuries CEDate basis: Period of manuscript composition
In the 1460s, al-Badrī gathered comments and verses in a work on wine and cannabis. Poets, historians and jurists offered praise, disapproval and conflicting judgments; regional and occupational names filled out the picture. The anthology preserves a conversation across different voices. Reading it means keeping those voices distinct, rather than turning them into a single account of what a whole society believed.
◌ Original research on historical manuscripts · 1 source
Read the evidence & its limits Harvard scholar Adam Bremer-McCollum’s 2025 research reflection examines fourteenth- and fifteenth-century Arabic sources by historians, jurists and poets. It dates al-Badrī’s two-part collection to the 1460s and discusses regional vocabulary alongside opposing evaluations. These are textual witnesses read through historical scholarship. Their different voices help document how people wrote and argued about cannabis; they are not population surveys or a chronology of the plant’s arrival.
Where the evidence stops These writings do not express a universal Islamic position, prove a first use, or establish that every region shared the same practices. Literary voices must remain distinct from direct observation.
09 / Fields, skilled hands, distant shores
Fibre at sea The Mary Rose · the Scheurrak SO1 wreck · 16th century CEDate basis: Period of surviving material objects
Hemp went to sea as working material. An anchor cable recovered from the Mary Rose and sailcloth from the Scheurrak wreck show how its fibres served aboard sixteenth-century ships. The Scheurrak vessel carried Baltic grain. After centuries underwater, these objects still connect the plant with the people who made ropes and sails, and with the ships that carried goods across the water.
◌ Surviving objects and conservation research · 4 sources
Read the evidence & its limits The Mary Rose conservation team identifies its recovered anchor cable as hemp, with more than one hundred metres raised. The ship sank in 1545. NICAS identifies Scheurrak SO1’s surviving sailcloth as hemp fabric. The Dutch Cultural Heritage Agency describes that wreck as a merchant ship carrying Baltic wheat, lost shortly before 1600. These are documented material objects, rather than a general claim about every ship of the period.
Where the evidence stops These finds do not establish that all contemporary sails were hemp, identify where these fibres grew, or prove a maritime first. Scheurrak’s exact sinking date remains uncertain.
10 / Exchange and administration
Knowledge under empire Colonial India · Calcutta and British medical publishing · 1839 / 1843 · 1893–94Date basis: Report publication and inquiry dates
O’Shaughnessy’s reports brought Indian and Persian knowledge into British medical publishing alongside his own observations. They did not begin the plant’s medical history. Decades later, the Indian Hemp Drugs Commission examined cultivation, trade and consumption under colonial rule. Its inquiry opposed total prohibition while considering harms and restrictions. Both records need to be read with their authors, purposes and unequal setting in view.
◌ Historical medical report and colonial inquiry · 3 sources
Read the evidence & its limits O’Shaughnessy’s 1843 journal publication identifies an earlier Calcutta report from 1839 and acknowledges Indian and Persian knowledge alongside his observations. The Indian Hemp Drugs Commission of 1893–94 subsequently assessed cultivation and consumption. Its report opposed total prohibition and favoured restriction through taxation, while considering harms and unintended effects. These are historical positions from a colonial inquiry, not the conclusions of a contemporary controlled clinical study.
Where the evidence stops O’Shaughnessy did not discover that cannabis had medicinal uses. The Commission’s conclusions should be attributed to its historical setting and cannot establish that cannabis is harmless or effective as a modern treatment.
11 / Agriculture and industry
Fibre for a wartime economy United States · Department of Agriculture · c. 1942Date basis: Approximate archival film date
The American wartime film Hemp for Victory follows hemp from the field into manufacture: growing the crop, harvesting stalks, separating fibre and making useful materials. It shows the people and machinery involved in that work. It also had a job to do: encourage production for the war effort. Watching it today means keeping that purpose in mind.
◌ Original government film and archival record · 1 source
Read the evidence & its limits The United States Department of Agriculture’s Hemp for Victory is dated circa 1942 in the National Agricultural Library archive. The film documents cultivation, harvesting and the manufacture and military uses of hemp fibre and coarse cloth. It is an original record of a specific wartime campaign, providing evidence of what that campaign promoted and how it presented the crop to its intended agricultural audience.
Where the evidence stops A wartime promotional film is not a neutral account of the plant’s entire history. It does not mark the invention of hemp fibre or imply unrestricted permission for all cannabis cultivation and use.
12 / Isolation and identification
A constituent becomes a structure Israel · cannabinoid chemistry · 1964Date basis: Research publication year
In 1964, Yehiel Gaoni and Raphael Mechoulam reported the isolation and structure of the compound we now call Δ9-THC. Researchers could study a defined molecule more precisely than a plant preparation whose composition might vary. That was an important step in understanding cannabis chemistry. Questions about its effects, risks and possible medical uses still needed their own experiments.
◌ Original chemical research · 1 source
Read the evidence & its limits Their April 1964 paper in the Journal of the American Chemical Society describes isolation, structural identification and partial synthesis of an active constituent of hashish. This is a foundational THC milestone, not the discovery of the first cannabinoid or the completion of every subsequent stereochemical and synthetic question. The historical publication date is 1964; a later date on a digital publisher record reflects online availability.
Where the evidence stops Identifying a molecule does not prove that a plant preparation treats a disease. THC chemistry should not be attributed to hemp seed oil or protein, and this paper was not a clinical trial.
13 / Law and plant parts
The importance of definitions India · the international treaty framework · 1985 · 1961 treaty contextDate basis: Act year with earlier treaty context
India’s 1985 NDPS Act distinguishes separated resin, flowering or fruiting tops, and specified preparations. Seeds and leaves are excluded from its definition of ganja when they are not accompanied by the tops. Those words matter: a plant is not a single legal category. Provisions for fibre and seed cultivation involve government authorization; the international treaty does not supply that permission by itself.
◌ Primary legal instruments · 2 sources
Read the evidence & its limits The NDPS Act was enacted on 16 September 1985 and came into force on 14 November. Section 2(iii) defines cannabis through charas, ganja and specified mixtures; seeds and leaves are excluded from ganja when unaccompanied by the tops. Section 14 allows government authorization, subject to conditions, for fibre, seed or horticulture. The 1961 Convention separately excludes cultivation exclusively for industrial fibre and seed or horticultural purposes from its application.
Where the evidence stops These provisions do not automatically authorize cultivation or establish blanket legality for bhang. This is historical legal context, not advice about a current activity; applicable permissions and rules depend on jurisdiction and circumstances.
14 / From chemistry to signalling
A binding site comes into view Laboratory research · publication milestone · November 1988Date basis: Research publication date
A labelled cannabinoid compound gave researchers a way to follow binding in rat-brain membranes. Their experiments identified a specific receptor site that could be measured and investigated. The question was becoming more precise: which biological structures respond to cannabinoids, and how? The receptor’s genetic instructions were still to be identified.
◌ Original laboratory experiment · 1 source
Read the evidence & its limits Devane and colleagues used a radiolabelled cannabinoid compound to characterize binding.
Where the evidence stops Animal-tissue binding is not a patient trial, and the receptor had not yet been cloned.
15 / From chemistry to signalling
The receptor’s genetic instructions Laboratory research · publication milestone · 9 August 1990Date basis: Research publication date
Matsuda and colleagues cloned the genetic instructions for the receptor now called CB1 and showed that it could function. A binding site could now be connected to a particular protein and its response. This opened a more detailed investigation of cannabinoid signalling, while leaving the body’s own signals to be identified.
◌ Original laboratory experiment · 1 source
Read the evidence & its limits The original paper reports cloning and functional expression of a cannabinoid-responsive G protein-coupled receptor.
Where the evidence stops This was a cloning milestone, not discovery of the entire endocannabinoid system or proof of a treatment benefit.
16 / From chemistry to signalling
A signal made within Laboratory research · publication milestone · 18 December 1992Date basis: Research publication date
The search moved from a plant compound to a molecule made within an animal. Researchers isolated anandamide from pig brain and found that it bound to the cannabinoid receptor. The receptor had an endogenous partner. This changed the scope of the investigation: scientists could ask how the body makes and uses its own cannabinoid signals.
◌ Original laboratory experiment · 1 source
Read the evidence & its limits The work identifies an endogenous ligand, rather than a constituent supplied by the plant.
Where the evidence stops It does not mean the body needs cannabis, or establish a benefit from consuming it.
17 / From chemistry to signalling
A second receptor Laboratory research · publication milestone · 2 September 1993Date basis: Research publication date
Another receptor expanded the picture. Munro, Thomas and Abu-Shaar reported the molecular characterization of what is now called CB2, including expression in splenic macrophages, a kind of immune cell. Cannabinoid signalling could no longer be described through the brain receptor alone. The finding opened biological questions; it did not demonstrate an immunity benefit from cannabis.
◌ Original laboratory experiment · 1 source
Read the evidence & its limits The original study reported receptor cloning and expression in splenic macrophages.
Where the evidence stops Its historical expression findings are not a complete modern map of CB2, and do not establish an immunity benefit.
18 / From chemistry to signalling
More than one internal signal Laboratory research · publication milestone · 29 June · 4 October 1995Date basis: Two research publication dates
Two teams approached another internal signal from different tissues. One studied canine gut; the other studied brain. Their 1995 papers identified a cannabinoid-receptor role for 2-arachidonoylglycerol, usually called 2-AG. Together with the earlier receptor and anandamide findings, the experiments were building a picture of signalling within the body, rather than a system explained by one plant molecule.
◌ Original laboratory experiment · 2 sources
Read the evidence & its limits Mechoulam and colleagues reported the intestinal-tissue finding in June; Sugiura and colleagues reported brain evidence in October.
Where the evidence stops These studies concern a cannabinoid-ligand role for an existing lipid. They do not map the complete signalling system or demonstrate clinical efficacy.
19 / A defined intervention
From mechanism to a trial Dravet syndrome · a randomized trial · 25 May 2017Date basis: Trial publication date
A trial published in 2017 compared a specified cannabidiol oral solution with placebo in 120 children and young adults with Dravet syndrome. Both were added to existing treatment. Convulsive seizures declined more with cannabidiol, but adverse events and withdrawals were also more frequent. A biological mechanism had become a clinical question with a measured benefit and costs.
◌ Randomized controlled trial · 1 source
Read the evidence & its limits The randomized, double-blind comparison lasted 14 weeks. These results concern that formulation, patient group and follow-up period.
Where the evidence stops This is evidence for a defined formulation and syndrome. It does not establish equivalent effects for seed oil, protein powder, every CBD preparation or all epilepsy.
Read the clinical evidence →
20 / Product-specific evidence
A medicine with a defined scope United States · Food and Drug Administration · 25 June 2018Date basis: Original US approval date
The FDA’s 2018 decision named a medicine and two conditions: Epidiolex, a cannabidiol oral solution, for seizures associated with Dravet and Lennox–Gastaut syndromes. Its original US authorization covered patients aged two years and older. This was a precise step from research into regulated care, with safety obligations attached. It did not extend the same evidence to every cannabis, CBD or hemp product.
◌ Original medicine approval and safety documentation · 1 source
Read the evidence & its limits The FDA’s original approval package for Epidiolex, dated 25 June 2018, covers seizures associated with Lennox–Gastaut syndrome or Dravet syndrome in patients aged two years and older at that time. The decision followed a product-specific assessment and included safety obligations, including attention to liver injury. This chapter records the initial 2018 authorization, rather than presenting its original indication and age range as the complete current prescribing label.
Where the evidence stops This approval does not cover hemp seed oil, protein, ordinary CBD products, whole cannabis or Mount Herbs goods. It is a U.S. regulatory milestone, not treatment guidance or a claim of universal safety.
Read the clinical evidence →
21 / The label evolves
A defined scope can change United States · FDA supplemental approval · 31 July 2020Date basis: Supplemental US approval date
The US authorization for Epidiolex expanded in 2020 to seizures associated with tuberous sclerosis complex and to patients aged one year and older. The medicine’s scope had changed through a further regulatory decision. Keeping the date beside that decision lets us distinguish the original 2018 approval from the later label.
◌ Official regulatory record · 1 source
Read the evidence & its limits The supplemental approval follows the original 2018 authorization for Dravet and Lennox–Gastaut syndromes.
Where the evidence stops This US decision is not an Indian authorization, universal cannabis approval or evidence for consumer seed products.
Read the clinical evidence →
22 / A precise policy shift
A change within the treaty United Nations · Commission on Narcotic Drugs · 2 December 2020Date basis: International decision date
In December 2020, the United Nations Commission on Narcotic Drugs voted to remove cannabis and cannabis resin from Schedule IV of the 1961 Convention. This changed their classification within the treaty and acknowledged their medical uses, while international controls remained. It did not decide the law in every country. Governments still made their own decisions within their domestic legal systems.
◌ Official international scheduling decision · 2 sources
Read the evidence & its limits Decision 63/17 was adopted on 2 December 2020 by 27 votes to 25, with one abstention. It deleted cannabis and cannabis resin from Schedule IV while their Schedule I status remained. The WHO’s explanation emphasized that international controls continued. The decision therefore should not be described as removing cannabis from all international schedules, legalizing it worldwide, or approving every cannabis-derived product as a medicine.
Where the evidence stops International rescheduling does not automatically rewrite every domestic law. This event establishes neither commercial permission for a particular product nor clinical efficacy for a particular preparation, condition or person.
23 / What was actually measured?
A common point of reference NIST · reference-material characterization · 20 June 2024Date basis: Technical report publication date
A dried, ground hemp material became a tool for checking laboratory measurements. NIST characterized Reference Material 8210 so laboratories could compare their cannabinoid and toxic-element results against common reference values. This quieter part of research matters: before interpreting a difference between samples, researchers need confidence in what their instruments measured.
◌ Official technical publication · 1 source
Read the evidence & its limits Reference Material 8210 has non-certified reference values intended for laboratory controls and research.
Where the evidence stops A reference material is not certification of a brand’s products, proof of purity or evidence of treatment benefit.
24 / Supportive cancer care
Relief is not tumour response Refractory chemotherapy nausea and vomiting · 16 August 2024Date basis: Trial online publication date
For people with chemotherapy nausea and vomiting despite standard medicines, a trial tested an added oral THC:CBD extract. More participants avoided vomiting and rescue medication during the measured period, while sedation and dizziness were more common. The question concerned support during cancer treatment. It did not test whether cannabis treated the tumour.
◌ Randomized phase II/III trial · 1 source
Read the evidence & its limits Among 147 evaluable participants, complete response was 24% with extract versus 8% with placebo. Sedation and dizziness were more common.
Where the evidence stops Complete response meant no emesis and no rescue medication over 0–120 hours. It was not a tumour response or complete absence of nausea.
Read the clinical evidence →
25 / An unfinished history
The map is still being made Global collections · questions across Asia · 2025Date basis: Research publication year
In 2025, researchers brought 193 genome assemblies into a shared cannabis pangenome. Comparing many plants revealed diversity that a single reference could miss. A divergent Tibetan genome reopened a question running through the whole story: which populations are wild, and which descend from cultivation? Wider sampling may change the answer. The history begins with inference, and it remains open to revision.
◌ Original comparative genomics and open questions · 1 source
Read the evidence & its limits Lynch and colleagues’ 2025 study assembled a cannabis pangenome resource comprising 193 genomes from 144 biological samples: 181 new assemblies and 12 existing ones. It documented extensive genomic diversity. A divergent Tibetan assembly contributed evidence suggesting wild relatives may persist in Asia, while the authors called for wider Asian and historical sampling. This complicates a simple account in which all wild progenitors have certainly disappeared.
Where the evidence stops One divergent genome does not prove a birthplace or settle wild versus feral status. A pangenome is a research resource, not evidence of a product’s clinical benefits or a final answer to domestication.
26 / The answer depends on the question
New studies. Different answers. Clinical trials · specific conditions and formulations · 2025–2026Date basis: Online and issue publication years
Recent studies have reached different answers about CBD and pain. In a larger fibromyalgia trial, placebo performed better than CBD. A small study of people with spinal cord injury found a modest signal of pain relief with CBD. To understand either result, we need to keep the condition, treatment and size of the study in view.
◌ Contrasting randomized trials · 2 sources
Read the evidence & its limits Condition, formulation, comparator and follow-up must remain attached to every result. Later studies may fall outside an earlier review’s search cutoff.
Where the evidence stops Selected evidence checked 3 October 2026; not an exhaustive or continuously updated review. Negative and uncertain results remain part of the story.
Read the clinical evidence →
Return to the valley and take a closer look at the plant itself: its leaf, seed and fibre.
Return to the living plant → Explore today’s medical evidence → 
Press cake
